SC 13D 1 schedule13d.htm SCHEDULE 13D Schedule 13D
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


SCHEDULE 13D
(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)

(Amendment No. ___)

APPLIED MEDICAL DEVICES, INC.
(Name of Issuer)


COMMON STOCK, PAR VALUE $0.001
(Title of Class of Securities)

38223103
(CUSIP Number)

Fountainhead Capital Partners Limited
Portman House, Hue Street
St. Helier, Jersey, Channel Islands JE4 5RP
+44 (0)1534 630112
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)


August 18, 2006
(Date of Event which Requires Filing Statement on Schedule 13D)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box [ ].

 
  1.
  NAMES OF REPORTING PERSONS
  IRS IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
  Fountainhead Capital Partners Limited
 
  2.
  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP                          (a) [__]
                                           (b) [__]
 
  3.
  SEC USE ONLY
 
 
  4.
  SOURCE OF FUNDS
 
  WC
  5.
  CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
  TO ITEM 2(e) or 2(f)                                                    [__]
 
  6.
  CITIZENSHIP OR PLACE OF ORGANIZATION
 
  Jersey, Channel Islands
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
7.
  SOLE VOTING POWER                    205,698,790
8.
  SHARED VOTING POWER                                                     0
9.
  SOLE DISPOSITIVE POWER                  205,698,790
10.
  SHARED DISPOSITIVE POWER                                            0
  11.
  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
  205,698,790
  12.
  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
  CERTAIN SHARES                                                    [__]
 
  13.
  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
  55%
  14.
  TYPE OF REPORTING PERSON
 
  CO
 
 
Item 1.   Security and Issuer

The name of the issuer is Applied Medical Devices, Inc., a Colorado corporation (the “Company”), which has its principal executive offices at 5528 Wescott Circle, Frederick, Maryland 21703. This statement relates to ’s common stock, no par value per share.

Item 2.    Identity and Background.

(a)-(f). This Schedule 13D is being filed by Fountainhead Capital Partners Limited, a Jersey corporation which has its principal executive offices at Portman House, Hue Street, St. Helier, Jersey, Channel Islands, JE4 5RP (the “Reporting Person”).

During the last five years, the Reporting Person has not been (A) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (B) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

Item 3.    Source and Amount of Funds or Other Consideration.

The Reporting Person received the securities covered by this statement pursuant to a Stock Purchase Agreement, dated August 18, 2006, by and among Company, certain shareholders and the Reporting Person (the “Stock Purchase Agreement”). Pursuant to the Stock Purchase Agreement, the Reporting Person paid a sum of $700,000 in exchange for 205,698,790 shares of Company Common Stock (the “Shares”). The Stock Purchase Agreement is more fully described in a current report on Form 8-K filed by Company on August 22, 2006.

Item 4.    Purpose of Transaction.

The Reporting Person has acquired the Shares pursuant to the Stock Purchase Agreement as described in Item 3 above. In connection with the Stock Purchase Agreement, there were changes to Company’s board of directors which were more fully described in the Form 8-K referenced above.

Except as set forth in this Schedule 13D and the Form 8-K referred to above, the Reporting Person has made no proposals, and has entered into no agreements, which would be related to or would result in any of the events or matters described in part (a) through (j) of Item 4 of Schedule 13D.

Item 5.    Interest in Securities of the Issuer.
 
(a)
The Reporting Person is the beneficial owner of 205,698,790 shares of the Company’s Common Stock, representing 55% of the outstanding shares of Company’s Common Stock on a fully diluted basis. The Reporting Person does not own any other securities of Company.

(b)
The Reporting Person has the sole power to vote and dispose of the 205,698,790 shares.

(c)
The Reporting Person did not effect any transactions in the issuer’s securities within the past 60 days.

(d)
No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Reporting Person’s securities.

(e)
Not applicable.
 

Item 6.   Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

Except as disclosed herein and in the current report on Form 8-K filed by Company on August 22, 2006, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Person and any other person with respect to any securities of the issuer, including, but not limited to transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

Item 7.   Material to be Filed as Exhibits.

None.
 

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 
Date:  August 22, 2006
 
 
 
/s/ Gisele Le Miere
 
Gisele Le Miere, Director
 
 
 
/s/ Eileen O’Shea
 
Eileen O’Shea, Director